REFINE-MS: A randomised, rater-blind, phase 3 trial to determine the optimal dose frequency of ocrelizumab for patients with relapsing remitting multiple sclerosis using a novel multi-arm multi-stage frequency-optimisation design (REFINE-MS)
Principal Investigator
Prof Gabriele DeLuca
Contact us
Email: dendron@ouh.nhs.uk
IRAS number
1013232